These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 27116710

  • 1. Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors.
    Mahal K, Biersack B, Schruefer S, Resch M, Ficner R, Schobert R, Mueller T.
    Eur J Med Chem; 2016 Aug 08; 118():9-20. PubMed ID: 27116710
    [Abstract] [Full Text] [Related]

  • 2. 4,5-Diaryl-3H-1,2-dithiole-3-thiones and related compounds as combretastatin A-4/oltipraz hybrids: Synthesis, molecular modelling and evaluation as antiproliferative agents and inhibitors of tubulin.
    Wang Z, Qi H, Shen Q, Lu G, Li M, Bao K, Wu Y, Zhang W.
    Eur J Med Chem; 2016 Oct 21; 122():520-529. PubMed ID: 27428395
    [Abstract] [Full Text] [Related]

  • 3. Anticancer properties of indole derivatives as IsoCombretastatin A-4 analogues.
    Pecnard S, Hamze A, Bignon J, Prost B, Deroussent A, Gallego-Yerga L, Peláez R, Paik JY, Diederich M, Alami M, Provot O.
    Eur J Med Chem; 2021 Nov 05; 223():113656. PubMed ID: 34171660
    [Abstract] [Full Text] [Related]

  • 4. Gold(I) biscarbene complexes derived from vascular-disrupting combretastatin A-4 address different targets and show antimetastatic potential.
    Muenzner JK, Biersack B, Kalie H, Andronache IC, Kaps L, Schuppan D, Sasse F, Schobert R.
    ChemMedChem; 2014 Jun 05; 9(6):1195-204. PubMed ID: 24648184
    [Abstract] [Full Text] [Related]

  • 5. Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models.
    Reipsch F, Biersack B, Lucas H, Schobert R, Mueller T.
    Int J Mol Sci; 2021 Dec 03; 22(23):. PubMed ID: 34884888
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and biological evaluation of indole-2-carbohydrazides and thiazolidinyl-indole-2-carboxamides as potent tubulin polymerization inhibitors.
    Kazan F, Yagci ZB, Bai R, Ozkirimli E, Hamel E, Ozkirimli S.
    Comput Biol Chem; 2019 Jun 03; 80():512-523. PubMed ID: 31185422
    [Abstract] [Full Text] [Related]

  • 7. Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action.
    Huang X, Huang R, Gou S, Wang Z, Liao Z, Wang H.
    Bioconjug Chem; 2016 Sep 21; 27(9):2132-48. PubMed ID: 27494235
    [Abstract] [Full Text] [Related]

  • 8. New indole-based chalconoids as tubulin-targeting antiproliferative agents.
    Mirzaei H, Shokrzadeh M, Modanloo M, Ziar A, Riazi GH, Emami S.
    Bioorg Chem; 2017 Dec 21; 75():86-98. PubMed ID: 28922629
    [Abstract] [Full Text] [Related]

  • 9. Synthesis, biological evaluation, and molecular docking studies of novel 1-benzene acyl-2-(1-methylindol-3-yl)-benzimidazole derivatives as potential tubulin polymerization inhibitors.
    Wang YT, Qin YJ, Yang N, Zhang YL, Liu CH, Zhu HL.
    Eur J Med Chem; 2015 Jun 24; 99():125-37. PubMed ID: 26070164
    [Abstract] [Full Text] [Related]

  • 10. Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.
    Mahal K, Resch M, Ficner R, Schobert R, Biersack B, Mueller T.
    ChemMedChem; 2014 Apr 24; 9(4):847-54. PubMed ID: 24678059
    [Abstract] [Full Text] [Related]

  • 11. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
    Ahn S, Hwang DJ, Barrett CM, Yang J, Duke CB, Miller DD, Dalton JT.
    Cancer Chemother Pharmacol; 2011 Feb 24; 67(2):293-304. PubMed ID: 20383708
    [Abstract] [Full Text] [Related]

  • 12. 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model.
    Schobert R, Biersack B, Dietrich A, Effenberger K, Knauer S, Mueller T.
    J Med Chem; 2010 Sep 23; 53(18):6595-602. PubMed ID: 20731355
    [Abstract] [Full Text] [Related]

  • 13. Design, Synthesis and Molecular Docking Studies of Novel Indole-Pyrimidine Hybrids as Tubulin Polymerization Inhibitors.
    Hu MJ, Zhang B, Yang HK, Liu Y, Chen YR, Ma TZ, Lu L, You WW, Zhao PL.
    Chem Biol Drug Des; 2015 Dec 23; 86(6):1491-500. PubMed ID: 26177395
    [Abstract] [Full Text] [Related]

  • 14. Substitution at the indole 3 position yields highly potent indolecombretastatins against human tumor cells.
    Álvarez R, Gajate C, Puebla P, Mollinedo F, Medarde M, Peláez R.
    Eur J Med Chem; 2018 Oct 05; 158():167-183. PubMed ID: 30216850
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Thiazolidinone Constraint Combretastatin Analogs as Novel Antitubulin Agents: Design, Synthesis, Biological Evaluation and Docking Studies.
    Sharma S, Gupta MK, Saxena AK, Bedi PM.
    Anticancer Agents Med Chem; 2017 Oct 05; 17(2):230-240. PubMed ID: 27141882
    [Abstract] [Full Text] [Related]

  • 17. New 6- and 7-heterocyclyl-1H-indole derivatives as potent tubulin assembly and cancer cell growth inhibitors.
    La Regina G, Bai R, Coluccia A, Naccarato V, Famiglini V, Nalli M, Masci D, Verrico A, Rovella P, Mazzoccoli C, Da Pozzo E, Cavallini C, Martini C, Vultaggio S, Dondio G, Varasi M, Mercurio C, Hamel E, Lavia P, Silvestri R.
    Eur J Med Chem; 2018 May 25; 152():283-297. PubMed ID: 29730191
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis and biological studies of novel tubulin inhibitors.
    Sun Y, Pandit B, Chettiar SN, Etter JP, Lewis A, Johnsamuel J, Li PK.
    Bioorg Med Chem Lett; 2013 Aug 01; 23(15):4465-8. PubMed ID: 23790539
    [Abstract] [Full Text] [Related]

  • 19. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
    Aoyama A, Katayama R, Oh-Hara T, Sato S, Okuno Y, Fujita N.
    Mol Cancer Ther; 2014 Dec 01; 13(12):2978-90. PubMed ID: 25313010
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis, and structure-activity relationships of pyrimido[4,5-b]indole-4-amines as microtubule depolymerizing agents that are effective against multidrug resistant cells.
    Devambatla RKV, Li W, Zaware N, Choudhary S, Hamel E, Mooberry SL, Gangjee A.
    Bioorg Med Chem Lett; 2017 Aug 01; 27(15):3423-3430. PubMed ID: 28610978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.